Astrazeneca (AZN) Operating Expenses (2009 - 2026)

Astrazeneca's Operating Expenses history runs 18 years deep, the most recent figure standing at -$8.4 billion for Q1 2026.

• In Q1 2026, Operating Expenses fell 9.95% year-over-year to -$8.4 billion; the TTM figure through Mar 2026 stood at -$34.9 billion (down 2.93% YoY), while the FY2025 annual figure was $34.2 billion, up 1.8% from the prior year.
• Operating Expenses was -$8.4 billion for Q1 2026 at Astrazeneca, up from -$9.4 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$6.7 billion in Q1 2023 to a low of -$10.1 billion in Q4 2024.
• Historically, Operating Expenses has averaged -$7.9 billion across 5 years, with a median of -$7.7 billion in 2023.
• Biggest YoY gain for Operating Expenses was 12.53% in 2022; the steepest drop was 90.12% in 2022.
• A 5-year view of Operating Expenses shows it stood at -$7.2 billion in 2022, then dropped by 16.53% to -$8.4 billion in 2023, then retreated by 19.46% to -$10.1 billion in 2024, then rose by 7.27% to -$9.4 billion in 2025, then gained by 10.07% to -$8.4 billion in 2026.
• The last three Operating Expenses figures came in at -$8.4 billion (Q1 2026), -$9.4 billion (Q4 2025), and -$8.7 billion (Q3 2025), per Business Quant data.